Abbreviations: DLT = dose limiting toxicity; MTD = maximum tolerated dose; WBC = white blood cell; LDH = lactate dehydrogenase; PR = partial response; PD = progressive disease; VEGF = vascular endothelial growth factor; CK = creatinine kinase; NCCN = National Comprehensive Cancer Network; ECOG = Eastern Cooperative Oncology Group.

Background and Highlights

- XPO1 is a nuclear transport oncogene overexpressed in a variety of cancers
- Inhibition of XPO1 has been clinically validated in multiple cancer types
- As of 31 Jul 2017, a total of 7 patients have been enrolled in the phase 1 dose-escalation study.

Inclusion / Exclusion

- Advanced solid tumors
- Metastatic or locally advanced and recurrent or refractory solid tumors
- Tumor shrinkage as defined by RECIST version 1.1

Clinical Activity

- Achieved stable disease (SD) while receiving SL 801 in 37.5% (9/24) of patients
- SD was observed in patients with colorectal cancer, anal squamous cell carcinoma, non-small cell lung cancer (NSCLC), and ovarian cancer.

Conclusions

- The disease control rate (DCR) is 63.8% (15/24) in the phase 1 cohort.
- The best response according to RECIST version 1.1 is SD in 9 patients (37.5%).

References

1. Turrisi A et al. BJU International 2012; 110: 1517–21
7. Sanz Lorenzo, Spain.

Acknowledgments: SL 801 was discovered by Stemline Therapeutics, Inc. and is being discovered and developed by Stemline Therapeutics, Inc. and Stemline Pharmaceuticals, Inc.